Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9551131 | 0.72 | — | — | |
| SCHEMBL23993233 | 0.71 | — | — | |
| SCHEMBL27186827 | 0.70 | HTT (0.42) | CETP | |
| SCHEMBL22605512 | 0.70 | — | — | |
| SCHEMBL613969 | 0.70 | — | — | |
| SCHEMBL7165275 | 0.69 | MEN1 (0.31) | — | |
| SCHEMBL4082432 | 0.68 | — | — | |
| SCHEMBL8735140 | 0.68 | MEN1 (0.46) | — | |
| SCHEMBL15241367 | 0.68 | — | — | |
| SCHEMBL15827471 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-20080234263-A1 | Quinazoline Derivatives | ASTRAZENECA (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070032513-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664030-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026156-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | CETP 4694/4885 |
| US-20080234263-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | CETP 4585/4885 |
| US-20070032513-A1 | Quinazoline derivatives | ERBB2, EGFR, ABL1 | CETP 4643/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | CETP 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.